Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome:a case-control study

Henry, N L, Pchejetski, D, A'Hern, R, Nguyen, A T, Charles, P, Waxman, J, Li, L, Storniolo, A M, Hayes, D F, Flockhart, D A, Stearns, V and Stebbing, J (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome:a case-control study. British Journal of Cancer, 103 (3). pp. 291-6. ISSN 0007-0920

Full text not available from this repository. (Request a copy)

Abstract

The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

Item Type: Article
Uncontrolled Keywords: aged,androstadienes,antineoplastic agents,aromatase inhibitors,breast neoplasms,bridged compounds,case-control studies,cytokines,estrogens,female,humans,inflammation,middle aged,musculoskeletal diseases,postmenopause,syndrome,tamoxifen,taxoids
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
?? ARM ??
Depositing User: Pure Connector
Date Deposited: 16 Dec 2014 10:06
Last Modified: 17 Oct 2018 15:32
URI: https://ueaeprints.uea.ac.uk/id/eprint/51536
DOI: 10.1038/sj.bjc.6605768

Actions (login required)

View Item